This segment focuses on the research, development, and commercialization of targeted therapies for women's cancers, with a primary focus on breast cancer. Research and development activities include the discovery and preclinical and clinical development of novel drug candidates, including OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader. The company utilizes advanced technologies and methodologies in drug discovery, including medicinal chemistry, pharmacology, and clinical trial design. The primary therapeutic area is estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The goal is to improve patient outcomes by providing effective and targeted treatments, addressing unmet medical needs in this patient population. Olema is strategically positioned to become a leader in the treatment of hormone-driven cancers. Future opportunities include expanding the pipeline and exploring additional indications. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials. Partnerships and collaborations are essential for advancing research and development efforts, as demonstrated by collaborations with other pharmaceutical companies.